日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes

在CAR-T细胞生成过程中,靶向BCL-2的治疗可通过非凋亡性适应性改变增强疗效。

Aboelella, Nada S; Park, Ryan; Tang, Erting; Asby, Nicholas; Ho, Joshua D; Pan, Tony; Wang, Sidney; Xie, Lishi; Kline, Justin P; Riedell, Peter A; Huang, Jun; LaBelle, James L

Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity.

聚合物-脂质混合纳米颗粒增强mRNA递送和T细胞介导的免疫反应。

Cai Xiaolei, Chen Min, Cao Guoshuai, Asby Nicholas, Elli Derek, Gula Haley, Nicolaescu Vlad, Nguyen Duy-Thuc, Huang Xiaodan, Dangi Tanushree, Solanki Ani, Woessner Sara, Zhang Wenbo, Tang Erting, Volpatti Lisa, Wallace Rachel, Pan Tony, Nguyen Mindy, Chen Qing, Geng Zhi, Sagar Rohin, Esser-Khan Aaron, Penaloza-MacMaster Pablo, Missiakas Dominique, Huang Jun

Two-Stage CD8(+) CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.

大B细胞淋巴瘤患者的两阶段CD8(+) CAR T细胞分化

Cao Guoshuai, Hu Yifei, Pan Tony, Tang Erting, Asby Nick, Althaus Thomas, Wan Jun, Riedell Peter A, Bishop Michael R, Kline Justin P, Huang Jun

Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.

Cilta-cel 通过驱动不同的免疫反应来挽救 ide-cel 在复发性多发性骨髓瘤中的治疗失败

Pan Tony, Tang Erting, Hu Yifei, Asby Nicholas, Schubat Mckenzie, Althaus Thomas, Riedell Peter A, Derman Benjamin, Huang Jun

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.

低强度 I 型干扰素信号传导可提高 CAR T 细胞治疗的疗效

Tang Erting, Hu Yifei, Cao Guoshuai, Asby Nicholas W, Nguyen Duy-Thuc, Aboelella Nada S, Ruiz Hanna, Zhao Yu, Xie Lishi, Chen Xiufen, Bishop Michael R, Riedell Peter A, LaBelle James L, Kline Justin P, Huang Jun

A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections

单细胞图谱揭示了SARS-CoV-2和HIV-1感染中共同和独特的免疫反应和代谢特征

Pan, Tony; Cao, Guoshuai; Tang, Erting; Zhao, Yu; Penaloza-MacMaster, Pablo; Fang, Yun; Huang, Jun